Whittier Trust Co. Has $993,000 Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Whittier Trust Co. raised its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 17.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,736 shares of the medical research company’s stock after buying an additional 716 shares during the period. Whittier Trust Co.’s holdings in ICON Public were worth $993,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Natixis Advisors LLC increased its holdings in ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock worth $37,279,000 after buying an additional 11,177 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in shares of ICON Public by 40.6% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after purchasing an additional 28,050 shares during the last quarter. Foyston Gordon & Payne Inc bought a new position in shares of ICON Public during the 3rd quarter valued at $11,672,000. Entropy Technologies LP lifted its stake in shares of ICON Public by 472.2% in the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after purchasing an additional 5,095 shares during the last quarter. Finally, Tributary Capital Management LLC boosted its holdings in ICON Public by 116.1% in the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock worth $828,000 after purchasing an additional 2,122 shares in the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ICLR has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Citigroup decreased their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Barclays dropped their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Truist Financial decreased their price objective on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Robert W. Baird cut their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.50.

ICON Public Stock Up 0.5 %

ICLR stock opened at $184.87 on Friday. ICON Public Limited has a twelve month low of $174.93 and a twelve month high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. The company has a market cap of $14.93 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The business’s 50-day simple moving average is $192.76 and its 200 day simple moving average is $226.31.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, research analysts anticipate that ICON Public Limited will post 13.38 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.